The FDA's decision to review the MRTP renewal applications for IQOS 2.4 and 3.0 systems by Philip Morris is crucial. A positive outcome can enhance the company's reputation and potentially increase sales of these products in the U.S. market. Given the significance of regulatory approvals in the tobacco industry, this review process is directly relevant to Philip Morris's business operations and could have a positive short-term impact on its stock price if the market anticipates a favorable outcome.